

Impact of Prior Authorizations Beyond Health Insurer Cost Savings

Prior authorization remains one of the most discussed barriers to timely quality cancer care delivery among health care providers. The burden placed on the multidisciplinary care team to submit authorizations, complete peer-to-peer interviews, and fight appeals is extraordinary.


By the Numbers




90% of oncologists experience delays in care due to prior authorizations.¹



80% of patients have experienced harm (including disease progression) due to prior authorization processes.¹



93% of patients were made to use a second-choice therapy from prior authorizations.¹



87% of patients were denied therapy through the prior authorization process.¹



REMEMBER: 3 Key Steps to Maximize Efficiency

1. Capture front end mistakes early.
2. Use prior authorization tips and guides to improve administrative efficiencies.
3. Track and audit denied authorizations and claims.

In 2023, the Association of Community Cancer Centers (ACCC) conducted a survey of its membership examining financial distress screening, measuring patient impact, and identifying challenges in helping patients access financial assistance programs.

Results from the survey show:

30%

30% of practices experience delays in insurance approvals.

32%

32% of respondents struggle to stay up to date with changing insurance requirements.

77%

77% of respondents have an integrated electronic health record (EHR) that allows for insurance verification.

16%

16% of cancer programs are tracking insurance optimization.*

14%

14% of cancer programs are tracking successful overturned appeals.*

*This shows a low number of financial advocates are tracking the patients they assist in choosing a different insurance.

+This shows that tracking (eg, obtained prior authorizations and overturned appeals) could be improved to ensure accountability and may help in payor contract negotiations.

In partnership with:



CANCERCARE®

This project is made possible by support from:

Genentech
A Member of the Roche Group

AMGEN

Seagen®

REFERENCES

1. American Society of Clinical Oncology (ASCO). Prior authorization. January 24, 2023. Accessed July 28, 2023. www.old-prod.asco.org/news-initiatives/current-initiatives/cancer-care-initiatives/prior-authorization



Association of Community Cancer Centers

© 2023. The Association of Community Cancer Centers (ACCC) is the leading education and advocacy organization for the cancer care community. For more information about this ACCC education program "Prior Authorization Clinic," visit acc-cancer.org/prior-authorization.